Intratumoral diversity of telomere length in individual neuroblastoma tumors

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7493-7503

  Pezzolo, Annalisa ^a   Pistorio, Angela ^a   Gambini, Claudio ^a   Haupt, Riccardo ^a   Ferraro, Manuela ^a   Erminio, Giovanni ^a   De Bernardi, Bruno ^a   Garaventa, Alberto ^a   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

ALT mechanism; Neuroblastoma; Telomerase; Telomere length

Indexed keywords

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CENTROMERE; CHILD; CHROMOSOMAL PARAMETERS; CHROMOSOME 2; CHROMOSOME ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FLUORESCENCE ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; SPANIARD; SURVIVAL TIME; TELOMERE HOMEOSTASIS; TELOMERE LENGTH; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; SURVIVAL ANALYSIS; TELOMERE; TUMOR CELL LINE;

TELOMERASE;

CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEUROBLASTOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TELOMERASE; TELOMERE;

EID: 84928412809     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2115     Document Type: Article

References (49)

1. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-573.
2. Zhou J, Richardson M, Reddy V, Menon M, Barrack ER, Reddy GP, Kim SH. Structural and functional association of androgen receptor with telomeres in prostate cancer cells. Aging (Albany NY). 2013;5:3-17.
3. Mitchell TR, Zhu XD. Methylated TRF2 associates with the nuclear matrix and serves as a potential biomarker for cellular senescence. Aging (Albany NY). 2014;6:248-263.
4. Blackburn EH. Telomere states and cell fates. Nature 2000;408: 53e6.
5. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nature 2005;6:611-622.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
7. Nakamura AJ, Redon CE, Bonner WM, Sedelnikova OA. Telomere-dependent and telomere-independent origins of endogenous DNA damage in tumor cells. Aging (Albany NY). 2009;1:212-218.
8. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res 2008;18:725-732.
9. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum Mol Genet 2005;2:191-196.
10. Li B, Reddy S, Comai L. Depletion of Ku70/80 reduces the levels of extrachromosomal telomeric circles and inhibits proliferation of ALT cells. Aging (Albany NY). 2011;3:395-406.
11. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumorderived cell lines. Nat Med 1997;3:1271-1274.
12. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 2001;10:1945-1952.
13. Tomaska L, Nosek J. Telomere heterogeneity: taking advantage of stochastic events. FEBS Lett 2009;583:1067-1071.
14. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
15. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216.
16. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-2211.
17. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397-411.
18. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47:561-571.
19. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-372.
20. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008;26:913-918.
21. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-591.
22. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG task force report. J Clin Oncol 2009;27:289-297.
23. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298-303.
24. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama Ji, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 2000;18:2582-2592.
25. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett 2003;194:221-233.
26. Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y. Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics. J Cancer Res 1992;83:159-164.
27. Binz N, Shalaby T, Rivera P, Shin-ya K, Grotzer MA. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 2005;41:2873-2881.
28. Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, Zaizov R, Yaniv I. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107:1391-1399.
29. Lundberg G, Sehic D, Länsberg JK, Øra I, Frigyesi A, Castel V, Navarro S, Piqueras M, Martinsson T, Noguera R, Gisselsson D. Alternative lengthening of telomeresan enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011;50:250-262.
30. Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, Ward RK, Lansdorp PM. Short telomeres on human chromosome 17p. Nat Genet 1998;18:76-80.
31. Ferlicot S, Youssef N, Feneux D, Delhommeau F, Paradis V, Bedossa P. Measurement of telomere length on tissue sections using quantitative fluorescence in situ hybridization (Q-FISH). J Pathol. 2003;200:661-666.
32. O'Sullivan JN, Finley JC, Risques RA, Shen WT, Gollahon KA, Moskovitz AH, Gryaznov S, Harley CB, Rabinovitch PS. Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry A 2004;58:120-131.
33. Narath R, Lörch T, Greulich-Bode KM, Boukamp P, Ambros PF. Automatic Telomere Length Measurements in Interphase Nuclei by IQ-FISH. Cytometry A 2005;68:113-120.
34. Canela A, Vera E, Klatt P, Blasco MA. High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci USA 2007;104:5300-5305.
35. Cafueri G, Parodi F, Pistorio ABertolotto M, Ventura F, Gambini C, Bianco P, Dallegri F, Pistoia V, Pezzolo A, Palombo D. Endothelial and smooth muscle cells from abdominal aortic aneurysm have increased oxidative stress and telomere attrition. PLoS One 2012;7:e35312.
36. Vera E, Blasco MA. Beyond average: potential for measurement of short telomeres. Aging (Albany NY). 2012;4:379-392. Review.
37. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333:425.
38. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IeM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179:1608-1615.
39. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-1071.
40. Campbell PJ. Telomeres and cancer: from crisis to stability to crisis to stability. Cell 2012;148:633-635.
41. Gocha AR, Nuovo G, Iwenofu OH, Groden J. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Am J Pathol 2013;182:41-48.
42. Tabori U, Wong V, Ma Jet, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C. Telomere maintenance and dysfunction predict recurrence in pediatric ependymoma. British Journal of Cancer 2008;99:1129-1135.
43. Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 2013;23:237-243.
44. von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H. snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis. Transl Oncol 2013;6:447-457.
45. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009;460:66-72.
46. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005;102:8222-8227.
47. Miettinen M, Chatten J, Paetau A, Stevenson A. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998;22:327-332.
48. Guidance for industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2001;Rockville
49. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials 1991;12:142S-158S.